← Leaderboards
Tetsuro Ikegami
University Of Texas Med Br Galveston
$3,820,605
Attributed
$3,820,605
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $402.8K · FY2011–24$500K$375K$250K$125K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,820,605 · 2
By mechanism
R01$3,820,605 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Med Br Galveston
Same institution · by research overlap
- Alexander Niclas Freiberg$3,141,620
- Alfredo G Torres$6,969,634
- Joseph Frank Petrosino$10,625,598
- Ricardo Rajsbaum$9,241,897
- Cheng Huang$1,016,501
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusViralMutantRuminantsVaccinationVaccinesImmunogenicMouse ModelPhenotypeRift Valley Fever VirusSafetyAttenuationEncephalitisVaccine CandidateCulicidaeGenerationsCountryImmunogenicityAttenuatedNational Institute Of Allergy And Infectious DiseaseRecombinantsRift Valley FeverCellsReverse Genetics
Grant awards (10)
Safety and immunogenicity of a novel Rift Valley fever candidate vaccine, RVax-1$386,125
R01 · FY2024 · AI · contact PI
Safety and immunogenicity of a novel Rift Valley fever candidate vaccine, RVax-1$386,125
R01 · FY2023 · AI · contact PI
Safety and immunogenicity of a novel Rift Valley fever candidate vaccine, RVax-1$386,125
R01 · FY2022 · AI · contact PI
Safety and immunogenicity of a novel Rift Valley fever candidate vaccine, RVax-1$369,885
R01 · FY2021 · AI · contact PI
Safety and immunogenicity of a novel Rift Valley fever candidate vaccine, RVax-1$402,795
R01 · FY2020 · AI · contact PI
Reverse genetics to develop a second generation Rift Valley fever vaccine$382,500
R01 · FY2015 · AI · contact PI
Reverse genetics to develop a second generation Rift Valley fever vaccine$382,500
R01 · FY2014 · AI · contact PI
Reverse genetics to develop a second generation Rift Valley fever vaccine$359,550
R01 · FY2013 · AI · contact PI
Reverse genetics to develop a second generation Rift Valley fever vaccine$382,500
R01 · FY2012 · AI · contact PI
Reverse genetics to develop a second generation Rift Valley fever vaccine$382,500
R01 · FY2011 · AI · contact PI